ALTERNATIVE TREATMENT FOR CLIMACTERIC SYNDROME

The paper considers the prevalence, diagnosis, and treatments of climacteric syndrome. It gives the results of an open-labeled comparative study of the eff iciency and safety of sagenit tablets 0.1 g used to treat patients with severe climacteric syndrome. The study enrolled 71 women. Later on all the examinees were divided into 2 groups: 1) 38 patients with severe manifestations of climacteric syndrome who were given sagenit (a study group) and 2) 33 apparently healthy women without clinical manifestations of climacteric syndrome (a control group). Positive results were obtained in relieving the symptoms of climacteric syndrome in the study group women just following a month of therapy; and after 3-month therapy the modified menopausal index was 30.9±1.70 scores in 98.3% of the study group women, which corresponded to the values in the control group.

climacteric syndrome, menopause, sagenit